Related Experiment Video
Updated: May 22, 2026

Combined In Vivo Anatomical and Functional Tracing of Ventral Tegmental Area Glutamate Terminals in the Hippocampus
Published on: September 9, 2020
Activation of alpha1-adrenoceptors enhances glutamate release onto ventral tegmental area dopamine cells
M C Velásquez-Martinez1, R Vázquez-Torres, C A Jiménez-Rivera
1Department of Physiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico, USA.
Abstract:
The ventral tegmental area (VTA) plays an important role in reward and motivational processes that facilitate the development of drug addiction. Glutamatergic inputs into the VTA contribute to dopamine (DA) neuronal activation related to reward and response-initiating effects in drug abuse. Previous investigations indicate that alpha1-adrenoreceptors (α1-ARs) are primarily localized at presynaptic elements in the ventral midbrain. Studies from several brain regions have shown that presynaptic α1-AR activation enhances glutamate release. Therefore, we hypothesized that glutamate released onto VTA-DA neurons is modulated by pre-synaptic α1-AR. Recordings were obtained from putative VTA-DA cells of male Sprague-Dawley rats (28-50 days postnatal) using voltage clamp techniques. Phenylephrine (10 μM) and methoxamine (80μM), both α1-AR agonists, increased AMPA receptor-mediated excitatory postsynaptic currents' (EPSCs) amplitude evoked by electrical stimulation of afferent fibers (p<0.05). This effect was blocked by the α1-AR antagonist prazosin (1 μM). Phenylephrine decreased the paired-pulse ratio (PPR) and increased spontaneous EPSCs' frequencies but not their amplitudes suggesting a presynaptic locus of action. No changes in miniature EPSCs (0.5μM, tetrodotoxin [TTX]) were observed after phenylephrine's application which suggests that α1-AR effect was action potential dependent. Normal extra- and intracellular Ca(2+) concentration seems necessary for the α1-AR effect since phenylephrine in low Ca(2+) artificial cerebrospinal fluid (ACSF) and depletion of intracellular Ca(2+) stores with thapsigargin (10 μM) failed to increase the AMPA EPSCs' amplitude. Chelerythrine (1μM, protein kinase C (PKC) inhibitor) but not Rp-cAMPS (11 μM, PKA inhibitor) blocked the α1-AR activation effect on AMPA EPSCs, indicating that a PKC intracellular pathway is required. These results demonstrated that presynaptic α1-AR activation modulates glutamatergic inputs that affect VTA-DA neuronal excitability. α1-AR action might be heterosynaptically localized at glutamatergic fibers terminating onto VTA-DA neurons. It is suggested that drug-induced changes in α1-AR could be part of the neuroadaptations occurring in the mesocorticolimbic circuitry during the addiction process.
Related Concept Videos
Adrenergic Neurons: Neurotransmission
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Sympathetic Signaling
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Affecting Neurotransmitter Release or Uptake

